Kinome Reprogramming Is a Targetable Vulnerability in ESR1 Fusion-Driven Breast Cancer

Transcriptionally active ESR1 fusions (ESR1-TAF) are a potent cause of breast cancer endocrine therapy (ET) resistance. ESR1-TAFs are not directly druggable because the C-terminal estrogen/anti-estrogen–binding domain is replaced with translocated in-frame partner gene sequences that confer constitu...

Descripción completa

Detalles Bibliográficos
Autores principales: Gou, Xuxu, Kim, Beom-Jun, Anurag, Meenakshi, Lei, Jonathan T., Young, Meggie N., Holt, Matthew V., Fandino, Diana, Vollert, Craig T., Singh, Purba, Alzubi, Mohammad A., Malovannaya, Anna, Dobrolecki, Lacey E., Lewis, Michael T., Li, Shunqiang, Foulds, Charles E., Ellis, Matthew J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2023
Materias:
Translational Cancer Biology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10543968/
https://www.ncbi.nlm.nih.gov/pubmed/37071495
http://dx.doi.org/10.1158/0008-5472.CAN-22-3484

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10543968/
https://www.ncbi.nlm.nih.gov/pubmed/37071495
http://dx.doi.org/10.1158/0008-5472.CAN-22-3484

Ejemplares similares